Solute carrier family 22 member 1 (OCT1) (SLC22A1)

The AMPK pathway via OCT1-mediated uptake describes a critical pharmacological axis primarily associated with the mechanism of action of the biguanide drug metformin. Solute carrier family 22 member 1 (OCT1) is the principal hepatic transporter responsible for the cellular entry of metformin. Once intracellular, metformin disrupts mitochondrial respiration at Complex I, leading to a shift in the cellular energy charge and the subsequent activation of AMP-activated protein kinase (AMPK). Activated AMPK serves as a master metabolic switch that inhibits hepatic gluconeogenesis, stimulates fatty acid oxidation, and improves insulin sensitivity. This pathway is a cornerstone in the treatment of type 2 diabetes, though its efficacy can be significantly influenced by genetic polymorphisms in the SLC22A1 gene that affect transporter function. Beyond glucose metabolism, this axis is being investigated for its potential roles in oncology and longevity due to the systemic effects of AMPK activation on cell growth and autophagy.

Other names

Organic cation transporter 1OCT1AMP-activated protein kinase pathway (downstream effector)SLC22A1

Metformin is transported into hepatocytes primarily via OCT1; once inside, it inhibits mitochondrial complex I, leading to an increased AMP:ATP ratio which activates AMPK to suppress gluconeogenesis.